Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 7/20 | 0.50 |
| ▸ | ESR1 | P03372 | 6/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.34 |
| ▸ | BCR | P11274 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.34 |
| ▸ | GLO1 | Q04760 | 3/20 | 0.34 |
| ▸ | OR51E2 | Q9H255 | 2/20 | 0.34 |
| ▸ | CD38 | P28907 | 1/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.34 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 0.34 |
| ▸ | TTR | P02766 | 2/20 | 0.34 |
| ▸ | SHBG | P04278 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31270617 | 1.00 | ESR2 (0.50) | ESR2ESR1MAOAMAOBTYR | |
| SCHEMBL5624423 | 0.84 | ESR2 (0.41) | ESR2ESR1MAOAMAOBTYR | |
| SCHEMBL677757 | 0.84 | ESR2 (0.41) | ESR2ESR1MAOAMAOBTYR | |
| SCHEMBL4183249 | 0.83 | HSD17B1 (0.38) | ESR2ESR1TYRCYP3A4CYP2C9 | |
| SCHEMBL13704314 | 0.81 | QDPR (0.43) | MAOBCD38MEN1KMT2APTGS1 | |
| SCHEMBL13704163 | 0.80 | QPCT (0.40) | ESR2ESR1TYRABCB1ALOX15 | |
| Idronoxil SCHEMBL149612 | 0.78 | ESR2 (0.49) | ESR2ESR1MAOAMAOBTYR | |
| Idronoxil SCHEMBL29353213 | 0.78 | ESR2 (0.49) | ESR2ESR1MAOAMAOBTYR | |
| SCHEMBL677785 | 0.77 | ESR2 (0.42) | ESR2ESR1MAOAMAOBTYR | |
| SCHEMBL15271030 | 0.75 | ESR1 (0.42) | ESR2ESR1MAOAMAOBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143588-A1 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD. | 2005-06-30 | — | — | US | claimed |
| EP-1153020-A4 | PRODUCTION OF ISOFLAVONE DERIVATIVES | NOVOGEN RES PTY LTD (AU) | 2002-08-21 | — | — | EP | claimed |
| EP-1153020-A1 | PRODUCTION OF ISOFLAVONE DERIVATIVES | Novogen Research Pty. Ltd. (AU) | 2001-11-14 | — | — | EP | claimed |
| WO-2000049009-A1 | PRODUCTION OF ISOFLAVONE DERIVATIVES | NOVOGEN RESEARCH PTY. LTD. (AU) | 2000-08-24 | — | — | WO | claimed |
| US-20120039917-A1 | IMMUNOMODULATING ACTIVITIES | MARSHALL EDWARDS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-7906554-B2 | Combination chemotherapy compositions and methods | NOVOGEN RESEARCH PTY LTD (AU) | 2011-03-15 | — | — | US | disclosed |
| US-7906554-B2 | Combination chemotherapy compositions and methods | NOVOGEN RESEARCH PTY LTD (AU) | 2011-03-15 | — | — | US | disclosed |
| US-7906660-B2 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD (AU) | 2011-03-15 | — | — | US | disclosed |
| US-20100152284-A1 | PREVENTION AND REVERSAL OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY | NOVOGEN RESEARCH PTY LTD (AU) | 2010-06-17 | — | — | US | disclosed |
| US-20100152284-A1 | PREVENTION AND REVERSAL OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY | NOVOGEN RESEARCH PTY LTD (AU) | 2010-06-17 | — | — | US | disclosed |
| WO-2008052256-A1 | PREVENTION AND REVERSAL OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY | NOVOGEN RESEARCH PTY LTD (AU) | 2008-05-08 | — | — | WO | disclosed |
| US-20080069900-A1 | Combination chemotherapy compositions and methods | NOVOGEN RESEARCH PTY LTD | 2008-03-20 | — | — | US | disclosed |
| US-20080069900-A1 | Combination chemotherapy compositions and methods | NOVOGEN RESEARCH PTY LTD | 2008-03-20 | — | — | US | disclosed |
| US-20060217564-A1 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD. | 2006-09-28 | — | — | US | disclosed |
| US-20050143588-A1 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD. | 2005-06-30 | — | — | US | disclosed |
| EP-1153020-A4 | PRODUCTION OF ISOFLAVONE DERIVATIVES | NOVOGEN RES PTY LTD (AU) | 2002-08-21 | — | — | EP | disclosed |
| EP-1153020-A1 | PRODUCTION OF ISOFLAVONE DERIVATIVES | Novogen Research Pty. Ltd. (AU) | 2001-11-14 | — | — | EP | disclosed |
| WO-2000049009-A1 | PRODUCTION OF ISOFLAVONE DERIVATIVES | NOVOGEN RESEARCH PTY. LTD. (AU) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152284-A1 | PREVENTION AND REVERSAL OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY | PMP22, NGF, GAP43 | ESR2 1769/4885ESR1 3617/4885MAOA 2076/4885 |
| US-20060217564-A1 | Production of isoflavone derivatives | CYP51A1, EGLN2, EGLN3 | ESR2 156/4885ESR1 232/4885MAOA 1190/4885 |
| US-20120039917-A1 | IMMUNOMODULATING ACTIVITIES | CD4, NFATC1, HRH2 | ESR2 43/4885ESR1 138/4885MAOA 2662/4885 |
| US-20050143588-A1 | Production of isoflavone derivatives | CYP51A1, EGLN2, EGLN3 | ESR2 156/4885ESR1 232/4885MAOA 1190/4885 |
| US-20080069900-A1 | Combination chemotherapy compositions and methods | TOP2A, IDH2, DHFR | ESR2 631/4885ESR1 447/4885MAOA 3106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.